CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Akcea
Therapeutics, Inc. today announced that it has filed a registration
statement on Form S-1 with the U.S. Securities and Exchange
Commission (SEC) relating to a proposed initial public offering of
its common stock. The number of shares to be offered and the price
range for the proposed offering have not been determined. Akcea has
applied to list its common stock on the Nasdaq Global Market under
the trading symbol "AKCA."
Cowen and Company, Stifel and Wells Fargo Securities are acting
as joint book running managers for the offering.
The proposed offering will be made only by means of a
prospectus. A copy of the preliminary prospectus, when available,
may be obtained from Cowen and Company, LLC, c/o Broadridge
Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus
Department, or by telephone at (631) 274-2806; or from Stifel,
Nicolaus & Company, Incorporated, One
Montgomery Street, Suite 3700, San
Francisco, CA 94104, or by telephone at (415) 364-2720, or
by email at syndprospectus@stifel.com; or from Wells Fargo
Securities, LLC, Attention: Equity Syndicate Department, 375 Park
Avenue, New York, NY 10152, or by
telephone at (800) 326-5897, or by email at
cmclientsupport@wellsfargo.com.
A registration statement relating to these securities has been
filed with the SEC but has not yet become effective. These
securities may not be sold, nor may offers to buy be accepted,
prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/akcea-therapeutics-files-registration-statement-for-proposed-initial-public-offering-300429489.html
SOURCE Ionis Pharmaceuticals, Inc.